

Pharmaceutical Sciences, 2025, 31(1), 22-42 [doi:10.34172/PS.](https://doi.org/10.34172/PS.024.40827)024.40827 <https://ps.tbzmed.ac.ir/>

Review Article

Vesicular Carriers for Follicular Drug Delivery

Mostafa Amirinejad1,[2](https://orcid.org/0000-0002-1054-7523) , Atoosa Haghighizadeh3 , Leila Etemad3,4, Omid Rajabi3,5[*](https://orcid.org/0000-0003-3127-2503)

 Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran. Department of Pharmaceutical Control, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Article Info

Article History: Received: 31 Aug 2024 Accepted: 7 Nov 2024 ePublished: 30 Nov 2024

- Keywords:
- -Invasome -Intrafollicular -Liposome
- -Niosome
- -Transferosome
- -Transfollicular

Introduction

Transdermal drug delivery systems have gained significant attention as a means to overcome the limitations associated with oral administration, such as the harsh pH environment, enzymatic degradation, mucus and epithelial barriers, and gastrointestinal microbiota,¹ as well as patient adherence following injection administration.² Although transdermal drug delivery has been challenged by the presence of non-permeable corneocytes and intact stratum corneum preventing skin penetration of large hydrophilic substances,^{3,4} pilosebaceous units act as feasibly permeable pathways for certain substances. The large surface area of the hair follicles provides an important absorption site for substances. In addition, they offer a portal and reservoir for dermally applied drugs.^{5,6} The transfollicular drug delivery system can be utilized as an alternative to transdermal drug delivery.7 Intrafollicular drug delivery plays an important role as a direct pathway to hair follicles. Androgenic alopecia⁸ and acne vulgaris⁹ are the most desired and studied disorders for intrafollicular delivery treatment.

However follicular delivery can bring notable advantages, but its application is limited by various challenges including size-selectivity of the follicles opening and sebum secretion fellow. Nanotechnology-based drug delivery systems have been demonstrated to be promising for overcoming follicular delivery-associated challenges.

Abstract

The follicular route has been explored for both topical and systemic drug delivery but its application is challenged by different limitations such as sebum flow and size-selectivity. Vesicular carriers like liposomes, niosomes, invasomes, and transferosomes, which have shown promise in overcoming these barriers, have been explored in this review study. These vesicles improve follicular penetration of drugs, with deformable carriers performing better than conventional liposomes. Also, modifying liposomes using permeation enhancers has been introduced as another choice to enhance their follicular penetration. Vesicular systems have been primarily used to deliver drugs for treating alopecia, acne, and topical infections. They have also demonstrated potential in systemic delivery of antihypertensive drugs and insulin. Local hair massage and iontophoresis techniques further improve vesicle follicular penetration.

> These systems enhance drug penetration and retention within the hair follicle.¹⁰ Polymeric nanoparticles can be engineered to have specific properties that improve drug delivery to the hair follicle and increase drug retention.^{9,11,12} Due to their small particle size, ranging from 1 to 100 nm, metallic nanoparticles can penetrate easily into the follicle root sheath.13,14 Dendrimers can be functionalized by targeting ligands that increase their specificity for the hair follicle.15 Solid lipid nanoparticles can encapsulate drugs and provide sustained release, improving drug retention within the hair follicle.^{16,17}

> Vesicular drug delivery systems (VDDSs) are wellknown assemblies of a lipid bilayer that are formed as a result of amphiphilic building blocks in contact with water in the shape of a spherical vesicle in which their hydrophilic heads are pointed toward the solution, and lipophilic tales are located inside 18. Based on different aims and components used in formation, so far, various types of vesicular carriers, including liposome,¹⁹ niosome,²⁰ transfersome,²¹ ethosome,²² and phytosome²³ have been developed. These vesicles can improve the dissolution rate of lipophilic drugs, 24 enhance the stability of the therapeutic agents, 25 prolong drug release time, 26 reduce the side effects of drugs by decreasing their uptake by unwanted tissues, 27 and increase the sensitivity of the therapeutic agents to the targeted location.²⁸ Due to their structural properties, overpassing stratum corneum might

*Corresponding Author: Omid Rajabi, E-mail: rajabio@mums.ac.ir

©2025 The Author(s). This is an open access article and applies the Creative Commons Attribution Non-Commercial License (http://creativecommons. org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.

be challenging for most vesicular carriers.²⁹ In addition to the enhanced permeation, the lipid state of VDDSs can help drugs interact with the follicular sebum and avoid their sebum flow-induced ejection, hence it can lead to increased retention.30

In this review article, the diverse landscape of follicular delivery using VDDSs, as promising nanomedicine carriers, has been studied. By examining the latest advancements and studies in this area, the objective is to offer a comprehensive overview of how VDDSs can enhance follicular delivery. The in-depth literature analysis aims to illuminate the potential benefits associated with utilizing VDDSs for follicular delivery as well as their optimization and improvement of their administration. By synthesizing key findings and identifying emerging trends, this review seeks to underscore the significance of VDDSs in improving the efficacy and precision of drug delivery to/through hair follicles. The review not only consolidates existing knowledge but also points towards future research directions and practical implications for optimizing therapeutic outcomes in dermatology and beyond.

Follicular drug delivery system *Follicle hair structure*

Basically, hair follicles comprise two main compartments, a hair bulb and a hair shaft, which is enveloped by a root sheath (Figure 1). The cells found near the hair bulb are responsible for regulating hair development.³¹ The bulge contains hair follicle stem cells and thus functions as the regulator of the hair cycle.32 In addition, the bulge is the insertion point of the musculus arrector pili.¹⁰ Moreover, one or more branched acinar-shaped sebaceous glands are connected to the upper region of each hair follicle through duct(s). These glands produce a lipid-enriched environment by sebum secretion. The interaction of a substance with the sebum is an essential factor in its penetration and permeation in hair follicles.33 The region between the skin surface and the insertion point of sebaceous glands is called the infundibulum. The infundibulum outer surface is covered by an impermeable stratum corneum. Its upper part is composed of an intact keratinized epidermis while the lower part is composed of trichilemmal which is notably more permeative.^{10,33}

Follicular delivery pathways

Follicle hair provides two main delivery which named Intrafollicular and transfollicular pathways. Intrafollicular is defined as passing way through the inner root sheath and targeting follicle hair. This pathway can be applied for the treatment of hair loss or follicle-related diseases.^{10,34} The transfollicular, as a subset of the transdermal delivery system, is an important pathway in systemic delivery. Since the stratum corneum inhibits the permeation of a broad variety of substances, the stratum corneum gap on the hair follicle can facilitate crossing the stratum corneum. After entering the hair follicle, released drugs can penetrate through the follicle membrane and make an entrance into

the dense network of blood capillaries, stem cells, and dendritic cells.10,35 So far, the transfollicular delivery of various lipophilic drug substances, such as celecoxib³⁶ and vaccines,³⁷ has been studied.

Follicular delivery challenges

Although follicular delivery can be a desirable delivery route, some challenges can limit the transport of many substances. The main difficulties are reviewed as follows.

The hair follicle openings are size-selective. However, in comparison to the 500 Da penetrability of skin³⁸ follicular delivery is considered more permeable for substances, but particle size still has been reported as a key factor in the extent and depth of follicular delivery systems.^{39,40} Patzelt *et al*. 41 demonstrated that the particles with 400 nm to 700 nm diameters, penetrated through hair follicles the most. Ghasemiyeh *et al*. 39 suggested 300 nm as the optimal size for hair follicle targeting.In addition, the maximal limit for penetration of particles into hair follicles was reported to be 7 µm. 42

Whereas the inactive hair follicles which neither grow nor produce sebum are impermeable to substances, $43,44$ sebum secretion led to challenging follicular penetration. The upward sebum flow can limit the movement of drugs⁴⁵ but since the flow is considerably slower than the penetration rate of nanoparticles, the secretion cannot prevent the nanoparticles from reaching the target.^{46,47}

In addition, another factor that limits a drug's penetrability is its hydrophilicity.⁴⁸ The lipophilic nature of sebum makes it difficult for hydrophilic drugs to penetrate through follicles. However, nanoparticles, particularly lipid-based nanoparticles such as liposomes and transferosomes, can encapsulate these drugs and facilitate their penetration into the follicle.10

Vesicular Drug Delivery Systems Ability for Follicular Delivery

VDDSs are a class of drug delivery systems that have attracted notable attention in drug delivery due to their ability to carry therapeutic agents in a controlled manner (Figure 2). These systems are colloidal dispersion comprising lipid or polymer-based vesicles that can encapsulate hydrophobic or hydrophilic drugs, protecting them from degradation and improving their bioavailability.49 VDDSs have been considered for dermal application due to their simplicity of surface modification, high compatibility, and suitability as vehicles for controlled delivery. 50,51 In addition, they have demonstrated notable permeation-enhancing abilities benefiting the dermal delivery of various medications.⁵² Therefore, they are suggested to be promising platforms for follicular delivery (Table 1). So far, different types of these vesicles, including liposomes, niosomes, and transferosomes, are studied for the follicular delivery of various active pharmaceutical ingredients which are reviewed further in detail (Table 2).

Vesicular Carriers for Follicular Drug Delivery

Liposomes

Liposomes are prepared with the emulsification of natural or synthetic lipids in an aqueous medium. They are mainly composed of a bilayer of phospholipids, cholesterol, and an aqueous medium.74 Liposomes are biologically inert and biodegradable, ensuring safety in their use. Their composition primarily consists of phospholipids, natural constituents of cell membranes, which minimizes the risk of toxicity, antigenicity, or pyrogenicity. Their adaptability to various sizes, compositions, and surface modifications allows for customization to meet specific formulation requirements. Liposomes are capable of encapsulating a wide array of hydrophilic and lipophilic drug substances, effectively protecting these substances from degradation by enzymes.75,76 Liposomes are utilized for different delivery routes such as dermal delivery.⁷⁷ Therefore, their application for follicular delivery was investigated in numerous studies. However, liposomes, due to their rigidity, are not as specified as deformable vesicles for follicular delivery.78

Table 1. Basic characterizations of different prepared vesicles.

Adapalene has been widely applied topically for the treatment of a pilosebaceous unit disorder, known as acne vulgaris.79 Since the action site of adapalene is the hair follicle, Kumar and Banga prepared adapalene-loaded liposomes for intrafollicular delivery. An *in vitro* permeation study showed that 15 hours after topical administration on porcine ear skin, hair follicle concentration of adapalene, when loaded into liposomes, was 4 times higher than conventional adapalene. However, there was no significant difference in the amount of adapalene recovered in the stratum corneum between liposomal and conventional solution formulations. Moreover, using confocal laser scanning microscopy (CLSM) revealed that in contrast to the adapalene solution in PEG 400 that could not penetrate through the hair shaft, the liposomes could traverse alongside it.⁵³

Kajimoto and co-workers⁸⁰ labeled dioleoyl phosphatidylethanolamine and insulin with two different fluorescent substances, 4-nitrobenzo-2-oxa-1,3-diazolyl, and rhodamine, respectively. Then, they prepared

Figure 1. Structure of hair Follicle.

liposomal insulin formulation using the labeled drug and phospholipid. They evaluated follicular delivery of the liposomal and conventional delivery of the labeled insulin, using both *in vivo* investigation on rat skin, immediately and 18 hours after topical application. In contrast to the plain solution of insulin which was not efficient in follicular penetration, considerable follicular delivery and site retention (18 hours after iontophoresis) of liposomes were observed. While topical minoxidil is an FDAapproved treatment for androgenic alopecia,⁸¹ applying tretinoin can enhance its efficiency by upregulation of follicular sulfotransferase enzymes.⁸² Therefore, Kochar *et al*. 62 loaded a combination of minoxidil and tretinoin into liposomes for intrafollicular delivery. The *ex vivo* permeation study on rat skin demonstrated that tretinoin could not penetrate through the skin, but minoxidil liposomes, after 6 hours, penetrated less than 20% through

the skin, whereas in combination with tretinoin in the liposomes, it could penetrate about 30%. They performed a CLSM investigation, using Rhodamine 6G (as minoxidil) and Coumarin 6 (as tretinoin), and displayed that the liposomes permeated skin through hair follicles.

In 2024, Liu *et al*. 56 claimed that Cardamonin can be effective in hair growth when used topically and prepared Cardamonin-loaded liposomes to increase its intrafollicular penetration. They performed an *in vitro* permeation study on mice skin. The liposome retentions from the hair follicles and dermis were 68.79 and 23.76 folds compared to the plain cardamonin. The test was repeated in porcine ear skin and the liposomal formulation penetrated significantly more than the free drug.

In 2018, Santos *et al.*,⁵⁷ compared follicular pathway effects on the cutaneous delivery of liposomes and nanostructured lipid carriers. They used voriconazole as the model drug,

Figure 2. Structure of the main vesicles for follicular delivery.

which is an anti-fungal medicine with broad systemic side effects.⁸³ They evaluated the permeation of voriconazoleloaded carriers through full-thickness excised porcine skin and re-evaluated them by applying follicle-blocked skin. It was demonstrated that after blockage of follicles, when liposomes were used as carriers, retention of liposomal drug from stratum corneum was increased by 10 times, and from the rest of the skin was decreased by 70%. They suggested the transfollicular delivery was the reason for improved penetration of liposomes through the porcine skin in comparison to nanostructured lipid carriers.⁵⁷

Jung *et al*. 54 measured the porcine hair follicle penetration depth of liposomal and conventional formulations, applying curcumin and carboxyfluorescein as model drugs due to their fluorescein properties. They performed an *ex vivo* study on porcine ear skin and evaluated the formulation's skin deposition by laser scanning microscopy. Both amphoteric and cationic liposomes had penetrated 69% of the follicle depth, 5 days after topical application. On the other hand, conventional liposomes could penetrate only about 30% of the follicle depth.

Since deformability is essential for penetration across follicles, using permeation enhancers has been studied to evaluate the efficiency of the liposomes' deformability on their penetrability. In 2016, Abd *et al.*⁵⁸ in order to produce deformable liposomes, added oleic acid to liposome formulation. Since caffeine efficiency in hair growth is demonstrated,⁸⁴ they prepared caffeine-loaded deformable liposomes and compared their intrafollicular delivery through abdominal full-thickness human skin in Franz diffusion cells with conventional liposomes and pure drugs. Caffeine retention from hair follicles for oleic acid-contained liposomes was 3.5 ± 0.7 μ g/cm², which was

significantly higher than conventional liposomes (1.7 ± 0.4) µg/cm2).58 Chloramphenicol can be applied as a treatment for topical infections.⁸⁵ Hsu et al.,⁶⁰ used deoxycholic acid as a permeation enhancer to prepare a flexible liposomal formulation for chloramphenicol. They performed an *in vitro* study on mouse dorsal skin to compare follicular penetration of the chloramphenicol loaded-deformable and rigid liposomes. A 3-fold improvement in follicular uptake of chloramphenicol was reported for the flexible liposomes compared with the rigid liposomes. Kumar *et al*. 61 loaded minoxidil into oleic acid-modified liposomes and investigated their *ex vivo* follicular permeation. Hair follicle retention of the oleic acid liposomal minoxidil gel after an *ex vivo* application on full-thickness pig ear skin was 4.48 ± 1.39 %, while minoxidil conventional solution retention was 0.45 ± 0.13 %. In addition, a CLSM study, 24 hours after topical administration, demonstrated that rhodamine B hair follicle penetrability was considerably higher in the liposomal gel formulation compared to the conventional solution (Figure 3).

To conclude, it can be claimed that deformability has an essential role in the penetrability of liposomes. Therefore, although liposomes have been demonstrated to be effective in the improvement of follicular permeation, flexible liposomal carriers, such as niosomes, invasomes, transferosomes, transethosomes, ethosomes, and cubosomes might be notably better choices compared to conventional liposomes. These liposomal vehicles are applied for the follicular delivery of various drugs which are reviewed as follows.

Niosomes

Niosomes are composed of a bilayer of non-ionic

Figure 3. Confocal laser scanning microscopy images of rhodamine B in conventional solution (upper) as control and oleic acid-modified liposomal gel formulation (lower) on porcine skin after 24 hours, showing brightfield (left) and fluorescence (right) images. Adapted from Ref. 61.

surfactants, including Brij,⁸⁶ Span,⁸⁷ and Tween,⁸⁸ and lipids such as cholesterol. The membrane enhances their skin deposition by reducing surface tension, enhancing vesicle flexibility, and increasing fusion with biological membranes.⁸⁹⁻⁹² Increased flexibility and fusion with biological membranes can lead to improved follicular delivery. Niosomes demonstrate improved stability over liposomes, which can be attributed to their high concentration of surfactants. This higher concentration not only enhances skin penetration but also leads to increased bioavailability.⁹³ Compared to the other vesicular carriers, niosomes exhibit enhanced patient adherence due to their non-lipidic composition. In addition, using non-ionic surfactants instead of lipids makes niosomes cheaper in cost and chemically more stable.⁹⁴ In addition, these surfactants have shown lower irritation than ionic surfactants.95

Finasteride, as an anti-androgenic agent, can effectively treat androgenic alopecia, but its systemic absorption is associated with serious systemic side effects.96 In order to avoid the side effects, Tabbakhian *et al*. 55 evaluated intrafollicular administration of finasteride after preparing finasteride-loaded negatively charged multilamellar liposomes and niosomes with >2 µm particle sizes. They compared their pilosebaceous unit targeting ratio to finasteride hydroalcoholic solution by applying the formulations to the ventral mid-section of the hamster ear in an *ex vivo* study. The pilosebaceous unit targeting ratios of multilamellar niosomes, multilamellar liposomes, and the hydroalcoholic solution were reported to be 0.38 ± 0.04 , 0.27 ± 0.04 , and 0.06 ± 0.01 , respectively. The results were in agreement with the studies suggesting that an increase in deformability could improve vesicles' follicular delivery. Furthermore, the study demonstrated that vesicles larger than 2 µm still had more affinity to pilosebaceous units in comparison to conventional substances. Furthermore, in 2023, Liu et al.,⁶⁶ applicated suspension, hydroethanolic solution, and niosomal formulation of finasteride on rat

skin to evaluate their transdermal delivery. They reported that 12 hours after application, the drug accumulation of the solution and niosomal formulation in hair follicles was 1.08 ± 0.06 µg/cm² and 21.04 ± 0.04 µg/cm². Furthermore, the suspension was not detected in the follicles. The results indicated the hair follicle targeting ability of niosomes was 20 times more than the solution. Moreover, the finasteride retention results from the full skin layer and stratum corneum for the solution were 26.9 ± 0.02 μg/cm² and 21.47 ± 0.08 µg/cm², and for the niosomes were 52.61 \pm 0.01 μg/cm² and 11.31 \pm 0.05 μg/cm². Therefore, though retention of niosomes from the stratum corneum was lower than the solution, drug retention below the stratum corneum was about 7 times more when applied in niosomal formulation compared to the conventional solution. According to the contrast in niosomes accumulation in the stratum corneum and below the stratum corneum, it can be concluded that the niosomes were delivered to the below stratum corneum through transfollicular delivery. Moreover, Rungseevijitprapa *et al*. 68 prepared finasterideloaded proniosomes to investigate their ability to hair growth stimulation in mice. They performed an *in vitro* study on the permeation of the proniosomes through porcine skin with or without blockage of the hair follicles. Twenty-four hours after topical application, proniosomes permeated through the conventional skin significantly more than the follicle-blocked porcine skin indicating the follicular penetration effect on the niosomes permeation. In addition, improved penetration of finasteride in niosomal formulation, compared to conventional solution form, through both follicle-blocked and non-blocked porcine skins, was displayed.

Topical retinoids and anti-androgens can treat acne vulgaris; therefore, topical administration of tretinoin, as a retinoid, and bicalutamide, as an anti-androgen, combination can result in a promising acne treatment.^{97,98} Ghasemiyeh et al.,⁶⁴ prepared a niosomal formulation of the bicalutamide and tretinoin combination to improve

Figure 4. Fluorescence images of hamster skin 2 hours after topical application, comparing rhodamine B solution (left) and rhodamine B-loaded niosomes (right). Hair follicles are indicated by arrows. Adapted from Ref. 64.

their intrafollicular delivery and pilosebaceous unit targeting. Using the fluorescence microscopy technique, they signified the predominant route of permeation and penetration of niosomes through skin and skin organelles and indicated that in contrast to the conventional gel formulation, niosomal gel significantly targeted the hair follicles (Figure 4).Furthermore, Manosroi *et al*. 65 suggested that the drug concentration reduction in blocked-hair follicles skin compared to opened-hair follicles skin was due to follicular delivery inhibition. Therefore, they concluded that *in vitro* follicular delivery of *Oryza sativa* (which has indicated notable ability in hair loss treatment after topical administration⁹⁹), after its topical application on porcine skin in conventional and niosomal solutions, was 0.312 ng and 1.849 ng, respectively, per follicle hair. Wu *et al.*,⁶⁷ compared transdermal delivery of aconitine through rat skin, in solution, tincture, and multilamellar niosomal formulations. Performing an *in vitro* deposition study on rat skin, they demonstrated that the concentration of the niosomes in hair follicles was significantly higher than in the solution and tincture.

Since alopecia areata is associated with an increase in free radicals, different anti-oxidants, including superoxide dismutase, can be considered alopecia areata treatments.¹⁰⁰ Karami *et al*. 63 produced niosomal superoxide dismutase for intrafollicular delivery. The *in vitro* permeation studies showed that the permeation of the niosomes through hairy and non-hairy guinea pig skin was 52.8 % and 20.8 %, 48 hours after topical administration. Hence, they suggested follicular delivery as its main delivery route which was in accordance with its high molecular weight and hydrophilic characteristics. On the other hand, conventional superoxide dismutase solution demonstrated 34.6 % and 12.4 % permeation through the mentioned skins, respectively, indicating that the niosomal formulation can permeate more feasibly in comparison with the conventional solution. Furthermore, they repeated the permeation test of both formulations after the extraction of lipids from

both skins. The only notably different result was the 40.6 % reduction of niosomes permeation through hairy skin after the lipid extraction. They concluded that the interaction between sebum and niosomes plays an important role in hair follicle accumulation of superoxide dismutase.

Invasomes

Invasomes are flexible vesicles consisting of a phospholipid bilayer, hydro-ethanolic core, and one or a mixture of terpenes.101 Ethanol can enhance the deformability of the membrane phospholipids creating a flexible structure resulting in permeation improvement.102 Terpenes can improve the penetrability by disrupting the stratum corneum lipids' tight structure.¹⁰³ However the potency of terpenes was demonstrated to be higher compared with other permeation enhancers, which resulted in more penetrability of invasomes than the other vesicles, but it is crucial to account for their toxicity.104 It is shown that utilizing natural terpenes, instead of synthetic ones, can considerably reduce their toxicity.105

In order to compare follicular penetration of conventional liposomes with invasomes to determine the effect of flexibility on penetrability, Trauer *et al*. 59 conjugated rhodamine to 1,2-Dipalmitoyl-sn-glycero-3-phosphorylethanolamines of the vesicles and loaded them with carboxyfluorescein to differentiate between the vesicles and release drug penetrability. With the aid of massaging, liposomes and invasomes reached penetration depths of 500 µm and 700 µm. However, carboxyfluorescein penetrated to an approximate depth of 1200 µm, regardless of the applied liposome type.

Topical isotretinoin is a promising medicine for acne vulgaris.106 In order to increase isotretinoin penetration through hair follicles and improve its pilosebaceous unit targeting, Dwivedi *et al*. 69 prepared isotretinoin invasomal gel. Using an *ex vivo* study, they demonstrated that after 8 hours of topical application of isotretinoin-loaded gels, the maximum drug permeated from the conventional gel was

Figure 5. Fluorescence images of pig ears 30 minutes after topical application of rhodamine B-labeled Phyllanthus emblica extract-loaded transferosomes (right) and the conventional solution (left). Adapted from Ref. 70.

31.97% \pm 1.31, and from the invasomal gel was 85.21 % \pm 1.88. In addition, applying CLSM, indicated that invasomes, in a gel formulation, could reach the pilosebaceous follicular unit traversing alongside the hair shaft. They showed that after 6 hours of topical application of rhodamine B, loaded into the conventional and invasomal gel, it could penetrate the depths of 20.24 μ m and 31.49 μ m.

Transferosomes

Transferosomes are composed of phospholipids, ethanol/ aqueous core, and edge activators, such as surfactants or bile salts, which help to destabilize the lipid bilayers and increase the deformability of the vesicles.107 This unique property allows transferosomes to squeeze themselves up to 5 to 10 times which is the most among vesicular carriers, through the narrow intercellular spaces of the stratum corneum, the outermost layer of the skin, and deliver drugs into the deeper layers.¹⁰⁸ Transferosomes are biocompatible and biodegradable as they are composed of natural phospholipids, transferosomes exhibit excellent biocompatibility and biodegradability. In addition, acting as a drug depot, transferosomes facilitate the slow and sustained release of their contents, which is beneficial for systemic and topical drug delivery.¹⁰⁹ They have shown great potential in enhancing the permeation of both hydrophilic and lipophilic drugs, and their ability to encapsulate a wide range of drug molecules makes them a promising carrier system for transdermal drug delivery.¹¹⁰ Hence, their penetrability into hair follicles is suggested to be considerable, and many researchers have evaluated their ability.

In 2022, Wongrakpanich *et al*. 70 revealed fluorescence images of rhodamine B-labeled Phyllanthus emblica extract-loaded transferosomes and solution after topical administration on pig ear skin. The successful intrafollicular delivery of the transferosomes, in comparison to the conventional solution, was indicated (Figure 5).In 2016, Abd *et al*. 58 performed a permeation study on full-thickness human skin in Franz diffusion cells. It was demonstrated that 24 hours after application, hair follicle permeation of caffeine loaded-transferosomes $(5.3 \pm 3.3 \text{ µg/cm}^2)$ was considerably more than conventional solution (0.8 ± 0.2) μ g/cm²), conventional liposomes (1.7 \pm 0.4 μ g/cm²), and niosomes $(2.2 \pm 0.5 \,\text{µg/cm}^2)$.

Fresta *et al.*,¹¹¹ compared pilosebaceous follicle targeting ability of transferosomes with hydroalcoholic solution, solid lipid nanoparticles, and liquid crystal nanocarriers. An hour after topical administration of different formulations of minoxidil on rat skin, transferosomes, solid lipid nanoparticles, liquid crystal nanocarriers, and hydroalcoholic solution demonstrated $47\% \pm 8$, $42\% \pm 9$, 91% \pm 7, and 13% \pm 8 presence in pilosebaceous follicle hair level respectively. After 48 hours, the presence in the mentioned level was reported to be $13\% \pm 7$, $18\% \pm 7$ 7, 74% \pm 8, and 1% \pm 0, respectively. It was concluded that although transferosomes showed immensely higher targeting and retention ability in comparison to the hydroalcoholic solution, their abilities were notably poorer than liquid crystal nanoparticles.It should be noted that in this study optimization has not been performed for the formulation of the transferosome sample; therefore, the results cannot be generalized and interpreted as the inferiority of transferosomes in follicular delivery.

Miscellaneous

Various vesicular systems have been investigated, so far. Flexible vesicles have the potential for follicular delivery due to their high permeability and penetrability. Thus far, follicular delivery of glycerosomes,¹¹² cubosomes,⁷³ hyalurosomes,¹¹² ethosomes,⁷¹ and transethosomes⁷² have been studied. Glycerosomes, a harmless and nontoxic topical drug delivery system, can be formed at room temperature unlike conventional liposomes.^{113,114} They exhibit improved entrapment, fluidity, and stability, while also increasing water content in the stratum corneum, effectively minimizing obstacles in transdermal drug delivery.¹¹⁵⁻¹¹⁷ Cubosomes demonstrate bioadhesive Cubosomes demonstrate bioadhesive properties, allowing for sustained release of incorporated drugs.118 Hyalurosomes containing hyaluronic acid, which has an affinity for CD44 receptors, are targeted for cells and tissues overexpressing this receptor. In addition, hyaluronic acid is commonly used as a moisturizing agent

Figure 6. Confocal laser scanning microscope photomicrographs (merge between fluorescence and transmitted lights) of 1% fluorescein diacetate solution (left) and fluoro-labeled transethosomes. Adapted from Ref. 72.

Vesicular Carriers for Follicular Drug Delivery

Amirinejad, *et al*.

Table 2. Continued.

Vesicular Carriers for Follicular Drug Delivery

Amirinejad, *et al*.

Vesicular Systems Efficiency through FDD

According to the *in vivo* studies, as a consequence of intrafollicular and transfollicular delivery, drug-loaded vesicles have demonstrated notable effects on the treatment of diseases in mice or rats. Their influences are reviewed and classified in intrafollicular and transfollicular as follows.

Intrafollicular

Hair follicle targeting as a result of intrafollicular delivery, can be a promising technique for treatment of hair loss. Therefore, various studies have evaluated the efficiency of different drugs after loading into vesicular carriers and applied for intrafollicular delivery.

Ciotti *et al*. 124 prepared minoxidil loaded-sodium sulfate modified-liposomes. They evaluated the minoxidil intrafollicular delivery in solution and rigid and flexible

liposomes, after daily topical administration on mice skin. They showed that the mean time for the appearance of "black skin" on mice was 16.4 ± 5.2 , 10.4 ± 3.3 , and 8.8 ± 1.5 days for solution, rigid liposomes, and flexible liposomes, respectively. In addition, it took 16.8 ± 4.1 days for rigid and 14.0 ± 3.7 days for flexible liposomes, for mice to get coated in full hair.

Co-loaded glycerosomes, hyalurosomes, liposomes, and glycerol-hyalurosomes by finasteride and baicalin were formulated and applied them topically, once daily, over the dorsal skin of mice and measured the mice hair length. On the 12th day of the study, the hair length of mice treated with finasteride and baicalin loaded into liposomes, glycerosomes, hyalurosomes, and glycerol-hyalurosomes, was 3.4 ± 0.4 mm, 3.7 ± 0.8 mm, 4.3 ± 0.4 mm, and 3.6 ± 0.5 mm, respectively. In addition, on the 21st day, treatment with the same formulations, caused 10.1 ± 0.9

mm, 9.8 ± 1.8 mm, 9.9 ± 1.4 mm, and 12.1 ± 1.6 mm hair growth, respectively. On the other hand, finasteride-only dispersion and liposome formulation managed to grow hair length up to 6.5 ± 0.9 mm and 8.1 ± 1.1 mm, 21 days after the beginning of the study.¹¹²

Rungseevijitprapa *et al*. 68 compared the hair growth stimulation ability of finasteride (1% w/v) proniosomes with finasteride (1% w/v) conventional solution and blank proniosomes (as the control group) after daily application on the dorsal skin of mice for four weeks. In contrast to finasteride conventional solution, the hair growth in the finasteride proniosomes-treated group was significantly improved compared with the control group.

The ability of minoxidil solution and cubosomal minoxidil was investigated to boost hair growth in Wistar rats. One mg/cm² of minoxidil 5 times/week was used and evaluated the hair growth using a 0-5 scoring system. After 3 weeks, the hair growth score of cubosomal minoxidiltreated rats was 4.2 ± 0.4 , while the score of minoxidil solution-treated rats was 2.2 ± 0.8 and the control group received a 1.2 ± 0.4 score.⁷³

Liu and coworkers administrated testosterone solution (5 mg/1 mL) topically in mice dorsal skin with the aim of inducing androgenic alopecia. Afterward, they shaved them and treated them with finasteride solution, minoxidil commercial solution (50 mg/1 mL), or niosomal finasteride twice daily. The regenerated hair weight in the mouse dorsal skin with the same area on the 28th day of the treatment presented the treatment performance quantitatively. The control group (non-alopecia-induced mice) demonstrated 56.4 mg regenerated hairs. The niosomal finasteride showed the most regeneration (49.4 mg) among treatments, which was more than the minoxidil group (44.1 mg) and the finasteride solution group (4.0 mg) .⁶⁶

Transfollicular

Transfollicular delivery can be a promising route for systemic absorption of drugs with low oral bioavailability. So far, the efficiency of olmesartan meoxomil and insulin in the treatment of hypertension and diabetes-induced rats has been studied.

In 2019, Albash *et al*. 72 induced hypertension in rats using methylprednisolone acetate $(171.00 \pm 4.00 \text{ mmHg})$ and compared the efficacy of transethosomal olmesartan medoxomil through the transfollicular delivery pathway to Angiosartan® 10 mg tablet. Transethosomes could maintain normal blood pressure values (127.50 ± 4.33 mmHg) up to 24 hours after administration. On the other hand, 8 hours after administration, angiotensin tablets failed (140.10 ± 6.40 mmHg) to keep the blood pressure at normal values (Figure 7).

The efficiency of transfollicular delivery of liposomal insulin with the aid of 1 hour of 0.45 mA/cm² iontophoresis, was evaluated on blood glucose levels in streptozocininduced diabetic Sprague Dawley rats. Blood glucose levels of non-treated and diabetic rats were 123 ± 6 mg/dL and 403 ± 56 mg/dL. Intraperitoneal injection of 5 UI/kg dose of insulin in diabetic rats led to an immediate decrease in blood glucose level. Four hours after the injection, the blood glucose level started increasing, and 18 hours after the injection, it returned to the basal level. On the other hand, topical administration of liposomal insulin with iontophoresis slowly reduced blood glucose level and decreased to about 20% of basal level 18 hours after iontophoresis, and the effect remained till 24 hours after iontophoresis.⁵³

Figure 7. Influence of oral administration of Angiosartan® tablet and transfollicular administration of transethosomal Olmesartan on Blood pressure level of methylprednisolone acetate -induced hypertensive rats. Values are mean ± SD of blood pressure level (mmHg) (n = 6). $*_p$ < 0.05, $_{*p}$ < 0.01, $_{*p}$ < 0.001, and $_{*p}$ < 0.0001 as compared to the negative control group (Tukey's multiple comparisons test). Data adapted from Ref.72.

Vesicular Systems Follicular Delivery-improvement Methods

In order to improve follicular delivery of different formulations, massaging and iontophoresis techniques have been studied. Their efficiency for vesicular carrierbased formulations has been demonstrated as follows.

Iontophoresis

Iontophoresis improves the permeation of drugs through barriers employing enhanced diffusion, direct electrophoresis, or electroosmosis.126-129 The use of iontophoresis can result in skin irritation or erythema at the application site when certain currents are applied. Studies have demonstrated that a current intensity below 0.5 mA/cm^2 is physiologically acceptable.¹³⁰⁻¹³²

Han *et al.*¹²⁵ investigated the iontophoresis effect on follicular delivery. They applied cationic liposomal and conventional formulations of Adriamycin topically on rat skin, with and without iontophoresis, and examined the drug transportation by fluorescence microscopy. It was indicated that 20 minutes of subsequent iontophoresis at 0.2 mA/cm² increased the fluorescence intensity of cationic liposomes from 85.7 to 214 and conventional solution from 33.0 to 52.5. The effect of iontophoresis on cationic liposomes was more intensive due to their increased positive charges and the doubled diffusive permeability. In 2011, Kajimoto et al. used iontophoresis to improve the penetration of insulin-loaded liposomes into Sprague Dawley rat follicles. They applied iontophoresis in 0.3 or 0.45 mA/cm2 current densities for either 1 or 2 hours. It was revealed that 1 hour of 0.45 mA/cm2 could improve penetration depth into follicles, significantly more than 1 or 2 hours of 0.3 mA/cm². On the other hand, continuing the 0.45 mA/cm² current for another hour significantly decreased the follicular delivery depth. The reduction might be caused by excluding the previously delivered liposomes from the follicles due to impairments such as long-time iontophoresis-induced inflammation.⁵³ Alvi *et al*.,133 in 2021, demonstrated that iontophoresis with 0.2 mA/cm² current enhanced the accumulation of goldcoated curcumin-loaded liposomes within the skin pores. In addition, they indicated that extending iontophoresis time from 5 to 20 minutes improved its efficiency in drug accumulation.

It should be noted that although sonophoresis has offered promising applications in transdermal delivery, it is not applied to follicular delivery. A study by Sarheed *et al*. 134 indicated that utilizing sonophoresis for 45 seconds during transdermal delivery. It was reported that increasing sonophoresis time led to a decrease in follicular contribution in transdermal delivery. It was explained that ultrasound disrupts the topmost corneocytes in the stratum corneum, decreasing barrier function and partially blocking the follicular orifice, which reduces follicular penetration.

Massaging has been proven to increase the follicular penetration depth of different substances.135,136 The safety and ease of the massaging process, compared to iontophoresis, make it more applicable and improve patient adherence. An *in-silico* simulation suggested that radial hair movement causes a flashing ratchet effect-like effect.137 So far, massaging has been applied with the aim of enhancing the penetration of different liposomal vesicles, including transferosomes,⁷⁰ niosomes, liposomes, and invasomes.59 Trauer *et al*. 59 demonstrated that 3 minutes of massaging could improve the penetrability of invasomes from 137.3 ± 26.5 µm to 698.8 ± 90.7 µm. In addition, the 3 minutes-massaging increased the penetration depth of liposomes from 93.2 ± 11.7 µm to 477.2 ± 61 µm. It means that although without massaging, both the liposomes and invasomes were not able to reach the bulge region or sebaceous gland, massaging enabled them to reach the target site.

Conclusion

Massage

In conclusion, vesicular carriers present a promising approach for enhancing follicular drug delivery. While conventional liposomes have shown limited efficacy due to their rigidity, deformable vesicles such as modified liposomes, transferosomes, niosomes, and invasomes exhibit greater potential for penetration through hair follicles. Techniques like topical hair massage and iontophoresis can further improve the penetrability of these vesicles.

Follicular delivery, as a non-invasive and patientcompliant topical route, holds significant potential for treating follicle-related disorders. The efficacy of vesicular carriers is further optimized through their adjustable particle size, enabling enhanced follicular delivery. Notably, current findings suggest that the transfollicular pathway plays a crucial role in transdermal delivery, making follicular delivery an attractive method for both topical treatments and systemic drug delivery.

The safety, non-toxic nature, and improved bioavailability of vesicular carriers, along with their superior elimination half-life compared to oral administration and intraperitoneal injection of plain drugs, make them an optimistic drug delivery option. Further research should explore the potential of vesicular drug delivery systems in the systemic delivery of various therapeutic agents and their application in different diseases. Moreover, investigating the follicular penetrability of other deformable vesicular carriers like menthosomes and flavosomes could yield valuable insights for future advancements in drug delivery.

Author Contributions

Mostafa Amirinejad: Conceptualization, Methodology, Formal Analysis, Data Curation, Writing - Original Draft. Atoosa Haghighizadeh: Formal Analysis Data Curation, Writing - Original Draft. Leila Etemad: Formal Analysis, Visualization, Writing - Review & Editing. Omid Rajabi:

Conceptualization, Project Administration, Supervision, Writing - Review & Editing.

Conflict of Interest

The authors claim that there is no conflict of interest.

References

- 1. Gambirasi M, Safa A, Vruzhaj I, Giacomin A, Sartor F, Toffoli G. Oral administration of cancer vaccines: Challenges and future perspectives. Vaccines. 2023;12(1):26. doi:10.3390/vaccines12010026
- 2. Taghizadeh B, Jaafari MR, Zarghami N. New insight into the importance of formulation variables on parenteral growth hormone preparations: Potential effect on the injection-site pain. Front Endocrinol (Lausanne). 2022;13:963336. doi:10.3389/fendo.2022. 963336
- 3. Schafer N, Balwierz R, Biernat P, Ochędzan-Siodłak W, Lipok J. Natural ingredients of transdermal drug delivery systems as permeation enhancers of active substances through the stratum corneum. Mol Pharm. 2023;20(7):3278-97. doi:10.1021/acs. molpharmaceut.3c00126
- 4. Sheng T, Luo B, Zhang W, Ge X, Yu J, Zhang Y, et al. Microneedle-mediated vaccination: Innovation and translation. Adv Drug Deliv Rev. 2021;179:113919. doi:10.1016/j.addr.2021.113919
- 5. Elmahdy A, Cao Y, Hui X, Maibach H. Follicular pathway role in chemical warfare simulants percutaneous penetration. J Appl Toxicol. 2021;41(6):964-71. doi:10.1002/jat.4081
- 6. Svenskaya YI, Genina EA, Parakhonskiy BV, Lengert EV, Talnikova EE, Terentyuk GS, et al. A simple non-invasive approach toward efficient transdermal drug delivery based on biodegradable particulate system. ACS Appl Mater Inter. 2019;11(19):17270-82. doi:10.1021/acsami.9b04305
- 7. Gu Y, Bian Q, Zhou Y, Huang Q, Gao J. Hair follicletargeting drug delivery strategies for the management of hair follicle-associated disorders. Asian J Pharm Sci. 2022;17(3):333-52. doi:10.1016/j.ajps.2022.04.003
- 8. He Z, Zhang Y, Liu Z, Guo T, Ai X, He Y, et al. Synergistic treatment of androgenetic alopecia with follicular co-delivery of minoxidil and cedrol in metal– organic frameworks stabilized by covalently crosslinked cyclodextrins. Int J Pharm 2024;654:123948. doi:10.1016/j.ijpharm.2024.123948
- 9. Kahraman E, Güngör S. Polymeric micellar nanocarriers of benzoyl peroxide as potential follicular targeting approach for acne treatment. Colloids Surf B Biointerfaces. 2016;146:692-9. doi:10.1016/j. colsurfb.2016.07.029
- 10. Patzelt A, Lademann J. Recent advances in follicular drug delivery of nanoparticles. Expert Opin Drug Deliv. 2020;17(1):49-60. doi:10.1080/17425247.2020. 1700226
- 11. Ferreira-Nunes R, Cunha-Filho M, Gratieri T, Gelfuso

GM. Follicular-targeted delivery of spironolactone provided by polymeric nanoparticles. Colloids Surf B Biointerfaces. 2021;208:112101. doi:10.1016/j. colsurfb.2021.112101

- 12. Lapteva M, Möller M, Gurny R, Kalia YN. Selfassembled polymeric nanocarriers for the targeted delivery of retinoic acid to the hair follicle. Nanoscale 2015;7(44):18651-62. doi:10.1039/c5nr04770f
- 13. Chandrakala V, Aruna V, Angajala G. Review on metal nanoparticles as nanocarriers: Current challenges and perspectives in drug delivery systems. Emergent Mater. 2022;5(6):1593-615. doi:10.1007/s42247-021- 00335-x
- 14. Friedman N, Dagan A, Elia J, Merims S, Benny O. Physical properties of gold nanoparticles affect skin penetration via hair follicles. Nanomedicine. 2021;36:102414. doi:10.1016/j.nano.2021.102414
- 15. Gökçe BB, Boran T, Emlik Çalık F, Özhan G, Sanyal R, Güngör S. Dermal delivery and follicular targeting of adapalene using PAMAM dendrimers. Drug Deliv Transl Res. 2021;11(2):626-46. doi:10.1007/s13346- 021-00933-6
- 16. Hamishehkar H, Ghanbarzadeh S, Sepehran S, Javadzadeh Y, Adib ZM, Kouhsoltani M. Histological assessment of follicular delivery of flutamide by solid lipid nanoparticles: Potential tool for the treatment of androgenic alopecia. Drug Dev Ind Pharm. 2016;42(6):846-53. doi:10.3109/03639045.2015.10628 96
- 17. Wosicka-Frąckowiak H, Cal K, Stefanowska J, Główka E, Nowacka M, Struck-Lewicka W, et al. Roxithromycin-loaded lipid nanoparticles for follicular targeting. Int J Pharm. 2015;495(2):807-15. doi:10.1016/j.ijpharm.2015.09.068
- 18. Jain S, Jain V, Mahajan S. Lipid based vesicular drug delivery systems. Adv Pharm. 2014;2014(1):574673. doi:10.1155/2014/574673
- 19. Orita Y, Shimanuki S, Okada S, Nakamura K, Nakamura H, Kitamoto Y, et al. Acoustic-responsive carbon dioxide-loaded liposomes for efficient drug release. Ultrason Sonochem. 2023;94:106326. doi:10.1016/j.ultsonch.2023.106326
- 20. Ekinci M, Çalışkan EE, Cakar B, Ilem-Ozdemir D, Uyanıkgil Yi, Çetin Uyanıkgil EO. [99mtc] technetiumlabeled niosomes: Radiolabeling, quality control, and in vitro evaluation. ACS Omega. 2023;8(7):6279-88. doi:10.1021/acsomega.2c06179
- 21. Rasheed MS, Ansari SF, Shahzadi I. Formulation, characterization of glucosamine loaded transfersomes and in vivo evaluation using papain induced arthritis model. Sci Rep. 2022;12(1):19813. doi:10.1038/ s41598-022-23103-1
- 22. Kumar S, Kumar A, Kumar N, Singh P, Singh TU, Singh BR, et al. In vivo therapeutic efficacy of curcuma longa extract loaded ethosomes on wound healing. Vet Res Commun. 2022;46(4):1033-49. doi:10.1007/ s11259-022-09952-1
- **37** | **Pharmaceutical Sciences, 2025, 31(1), 22-42**
- 23. Omidfar F, Gheybi F, Davoodi J, Amirinejad M, Badiee A. Nanophytosomes of hesperidin and of hesperetin: Preparation, characterization, and in vivo evaluation. Biotechnol Appl Biochem. 2023;70(2):846-56. doi:10.1002/bab.2404
- 24. 24. Ockun MA, Baranauskaite J, Uner B, Kan Y, Kırmızıbekmez H. Preparation, characterization and evaluation of liposomal-freeze dried anthocyaninenriched vaccinium arctostaphylos l. Fruit extract incorporated into fast dissolving oral films. J Drug Deliv Technol. 2022;72:103428. doi:10.1016/j. jddst.2022.103428
- 25. Huang M, Wang J, Tan C, Ying R, Wu X, Chen W, et al. Liposomal co-delivery strategy to improve stability and antioxidant activity of trans-resveratrol and naringenin. Int J Food Sci Technol. 2022;57(5):2701- 14. doi:10.1111/ijfs.15486
- 26. Tang C, Yin D, Liu T, Gou R, Fu J, Tang Q, et al. Maleimide-functionalized liposomes: Prolonged retention and enhanced efficacy of doxorubicin in breast cancer with low systemic toxicity. Molecules. 2022;27(14):4632. doi:10.3390/molecules27144632
- 27. Amirinejad M, Davoodi J, Abbaspour MR, Akhgari A, Hadizadeh F, Badiee A. Preparation, characterization and improved release profile of ibuprofenphospholipid association. J Drug Deliv Technol. 2020;60:101951. doi:10.1016/j.jddst.2020.101951
- 28. Makwana V, Karanjia J, Haselhorst T, Anoopkumar-Dukie S, Rudrawar S. Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization. Int J Pharm .2021;593:120117. doi:10.1016/j.ijpharm.2020.120117
- 29. Singh Malik D, Mital N, Kaur G. Topical drug delivery systems: A patent review. Expert Opin Ther Pat. 2016;26(2):213-28. doi:10.1517/13543776.2016.11312 67
- 30. Betz G, Imboden R, Imanidis G. Interaction of liposome formulations with human skin in vitro. Int J Pharm. 2001;229(1):117-29. doi:10.1016/S0378- 5173(01)00824-9
- 31. Verma A, Jain A, Hurkat P, Jain SK. Transfollicular drug delivery: Current perspectives. Res Rep Transderm Drug Deliv. 2016;2016:5. doi: 10.2147/RRTD.S75809
- 32. Koester J, Miroshnikova YA, Ghatak S, Chacón-Martínez CA, Morgner J, Li X, et al. Niche stiffening compromises hair follicle stem cell potential during ageing by reducing bivalent promoter accessibility. Nat Cell Biol. 2021;23(7):771-81. doi:10.1038/s41556- 021-00705-x
- 33. Blume-Peytavi U, Vogt A. Human hair follicle: Reservoir function and selective targeting. Br J Dermatol. 2011;165 Suppl 2:13-7. doi:10.1111/j.1365- 2133.2011.10572.x
- 34. Beg MA, Ginther OJ. Follicle selection in cattle and horses: Role of intrafollicular factors. Reproduction. 2006;132(3):365-77. doi:10.1530/rep.1.01233
- 35. Blume-Peytavi U, Massoudy L, Patzelt A, Lademann J,

Dietz E, Rasulev U, et al. Follicular and percutaneous penetration pathways of topically applied minoxidil foam. Eur J Pharm Biopharm. 2010;76(3):450-3. doi:10.1016/j.ejpb.2010.06.010

- 36. Soliman SM, Abdel Malak NS, El-Gazayerly ON, Abdel Rehim AA. Formulation of microemulsion gel systems for transdermal delivery of celecoxib: In vitro permeation, anti-inflammatory activity and skin irritation tests. Drug Discov Ther. 2010;4(6):459-71.
- 37. Hansen S, Lehr C-M. Transfollicular delivery takes root: The future for vaccine design? Expert Rev Vaccines. 2014;13(1):5-7. doi:10.1586/14760584.2014 .862500
- 38. Bos JD, Meinardi MM. The 500 dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165-9. doi:10.1034/j.1600- 0625.2000.009003165.x
- 39. Ghasemiyeh P, Azadi A, Daneshamouz S, Heidari R, Azarpira N, Mohammadi-Samani S. Cyproterone acetate-loaded nanostructured lipid carriers: Effect of particle size on skin penetration and follicular targeting. Pharm Dev Technol. 2019;24(7):812-23. doi :10.1080/10837450.2019.1596133
- 40. Su R, Fan W, Yu Q, Dong X, Qi J, Zhu Q, et al. Size-dependent penetration of nanoemulsions into epidermis and hair follicles: Implications for transdermal delivery and immunization. Oncotarget. 2017;8(24):38214-26. doi:10.18632/oncotarget.17130
- 41. Patzelt A, Richter H, Knorr F, Schäfer U, Lehr CM, Dähne L, et al. Selective follicular targeting by modification of the particle sizes. J Control Release. 2011;150(1):45-8. doi:10.1016/j.jconrel.2010.11.015
- 42. Rolland A, Wagner N, Chatelus A, Shroot B, Schaefer H. Site-specific drug delivery to pilosebaceous structures using polymeric microspheres. Pharm Res. 1993;10(12):1738-44. doi:10.1023/a:1018922114398
- 43. Lademann J, Knorr F, Richter H, Blume-Peytavi U, Vogt A, Antoniou C, et al. Hair follicles--an efficient storage and penetration pathway for topically applied substances. Summary of recent results obtained at the center of experimental and applied cutaneous physiology, charité -universitätsmedizin berlin, germany. Skin Pharmacol Physiol. 2008;21(3):150-5. doi:10.1159/000131079
- 44. Lademann J, Otberg N, Richter H, Weigmann HJ, Lindemann U, Schaefer H, et al. Investigation of follicular penetration of topically applied substances. Skin Pharmacol Appl Skin Physiol. 2001;14 Suppl 1:17-22. doi:10.1159/000056385
- 45. Meidan VM, Bonner MC, Michniak BB. Transfollicular drug delivery--is it a reality? Int J Pharm. 2005;306(1- 2):1-14. doi:10.1016/j.ijpharm.2005.09.025
- 46. Lademann J, Richter H, Schaefer UF, Blume-Peytavi U, Teichmann A, Otberg N, et al.. Hair follicles - a long-term reservoir for drug delivery. Skin Pharmacol Physiol 2006;19(4):232-6. doi:10.1159/000093119
- 47. Wosicka H, Cal K. Targeting to the hair follicles:

Current status and potential. J Dermatol Sci. 2010;57(2):83-9. doi:10.1016/j.jdermsci.2009.12.005

- 48. Ita KB. Chemical penetration enhancers for transdermal drug delivery - success and challenges. Curr Drug Deliv. 2015;12(6):645-51. doi:10.2174/156 7201812666150804104600
- 49. Alenzi AM, Albalawi SA, Alghamdi SG, Albalawi RF, Albalawi HS, Qushawy M. Review on different vesicular drug delivery systems (vddss) and their applications. Recent Pat Nanotechnol. 2023;17(1):18- 32. doi:10.2174/1872210516666220228150624
- 50. Pandey M, Choudhury H, Gorain B, Tiong SQ, Wong GYS, Chan KX, et al. Site-specific vesicular drug delivery system for skin cancer: A novel approach for targeting. Gels. 2021;7(4):218. doi:10.3390/ gels7040218
- 51. Witika BA, Mweetwa LL, Tshiamo KO, Edler K, Matafwali SK, Ntemi PV, et al. Vesicular drug delivery for the treatment of topical disorders: Current and future perspectives. J Pharm Pharmacol. 2021;73(11):1427-41. doi:10.1093/jpp/rgab082
- 52. Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: Reviewing three decades of research. Int J Pharm. 2007;332(1- 2):1-16. doi:10.1016/j.ijpharm.2006.12.005
- 53. Kumar V, Banga AK. Intradermal and follicular delivery of adapalene liposomes. Drug Dev Ind Pharm. 2016;42(6):871-9. doi:10.3109/03639045.201 5.1082580
- 54. Jung S, Otberg N, Thiede G, Richter H, Sterry W, Panzner S, et al. Innovative liposomes as a transfollicular drug delivery system: Penetration into porcine hair follicles. J Invest Dermatol. 2006;126(8):1728-32. doi:10.1038/ sj.jid.5700323
- 55. Tabbakhian M, Tavakoli N, Jaafari MR, Daneshamouz S. Enhancement of follicular delivery of finasteride by liposomes and niosomes 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models. Int J Pharm. 2006;323(1-2):1-10. doi:10.1016/j.ijpharm.2006.05.041
- 56. Liu Z, He Z, Ai X, Guo T, Feng N. Cardamonin-loaded liposomal formulation for improving percutaneous penetration and follicular delivery for androgenetic alopecia. Drug Deliv Transl Res. 2024;14(9):2444-60. doi:10.1007/s13346-024-01519-8
- 57. Santos GA, Angelo T, Andrade LM, Silva SMM, Magalhães PO, Cunha-Filho M, et al. The role of formulation and follicular pathway in voriconazole cutaneous delivery from liposomes and nanostructured lipid carriers. Colloids Surf B Biointerfaces. 2018;170:341-6. doi:10.1016/j.colsurfb.2018.06.037
- 58. Abd E, Roberts MS, Grice JE. A comparison of the penetration and permeation of caffeine into and through human epidermis after application in various vesicle formulations. Skin Pharmacol Physiol. 2016;29(1):24-30. doi:10.1159/000441040
- 59. Trauer S, Richter H, Kuntsche J, Büttemeyer R,

Liebsch M, Linscheid M, et al. Influence of massage and occlusion on the ex vivo skin penetration of rigid liposomes and invasomes. Eur J Pharm Biopharm. 2014;86(2):301-6. doi:10.1016/j.ejpb.2013.11.004

- 60. Hsu CY, Yang SC, Sung CT, Weng YH, Fang JY. Antimrsa malleable liposomes carrying chloramphenicol for ameliorating hair follicle targeting. Int J Nanomedicine. 2017;12:8227-38. doi:10.2147/ijn. S147226
- 61. Kumar P, Singh SK, Handa V, Kathuria H. Oleic acid nanovesicles of minoxidil for enhanced follicular delivery. Medicines (Basel). 2018;5(3):103. doi:10.3390/medicines5030103
- 62. Kochar P, Nayak K, Thakkar S, Polaka S, Khunt D, Misra M. Exploring the potential of minoxidil tretinoin liposomal based hydrogel for topical delivery in the treatment of androgenic alopecia. Cutan Ocul Toxicol. 2020;39(1):43-53. doi:10.1080/15569527.201 9.1694032
- 63. Karami MA, Jalili Rad M, Zadeh BSM, Salimi A. Superoxide dismutase loaded niosomes delivery to hair follicles: Permeation through synthetic membrane and guinea pig skin. Int J App Pharm. 2019;11(5):305- 12. doi:10.22159/ijap.2019v11i5.34289
- 64. Ghasemiyeh P, Moradishooli F, Daneshamouz S, Heidari R, Niroumand U, Mohammadi-Samani S. Optimization, characterization, and follicular targeting assessment of tretinoin and bicalutamide loaded niosomes. Sci Rep. 2023;13(1):20023. doi:10.1038/s41598-023-47302-6
- 65. Manosroi A, Ruksiriwanich W, Abe M, Manosroi W, Manosroi J. Transfollicular enhancement of gel containing cationic niosomes loaded with unsaturated fatty acids in rice (oryza sativa) bran semi-purified fraction. Eur J Pharm Biopharm. 2012;81(2):303-13. doi:10.1016/j.ejpb.2012.03.014
- 66. Liu X, Guo F, Liang D, Li Z, Cao Y, Chen M, et al. Development and evaluation of finasteride niosomes targeting to hair follicles for the management of androgenic alopecia. J Drug Deliv Technol. 2023;86:104725. doi:10.1016/j.jddst.2023.104725
- 67. Wu T, Zhu C, Wang X, Kong Q, Guo T, He Z, et al. Cholesterol and phospholipid-free multilamellar niosomes regulate transdermal permeation of a hydrophobic agent potentially administrated for treating diseases in deep hair follicles. J Pharm Sci. 2022;111(6):1785-97. doi:10.1016/j.xphs.2021.08.016
- 68. Rungseevijitprapa W, Wichayapreechar P, Sivamaruthi BS, Jinarat D, Chaiyasut C. Optimization and transfollicular delivery of finasteride-loaded proniosomes for hair growth stimulation in c57bl/6mlac mice. Pharmaceutics. 2021;13(12):2177. doi:10.3390/pharmaceutics13122177
- 69. Dwivedi M, Sharma V, Pathak K. Pilosebaceous targeting by isotretenoin-loaded invasomal gel for the treatment of eosinophilic pustular folliculitis: Optimization, efficacy and cellular analysis. Drug Dev

Ind Pharm. 2017;43(2):293-304. doi:10.1080/0363904 5.2016.1239628

- 70. Wongrakpanich A, Leanpolchareanchai J, Morakul B, Parichatikanond W, Teeranachaideekul V. Phyllanthus emblica extract-loaded transfersomes for hair follicle targeting: Phytoconstituents, characterization, and hair growth promotion. J Ole Sci 2022;71(7):1085-96. doi:10.5650/jos.ess21425
- 71. Fouad SA, Khatab ST, Teaima MH, El-Nabarawi MA, Abdelmonem R. Nanosized ethosomal dispersions for enhanced transdermal delivery of nebivolol using intradermal/transfollicular sustained reservoir: In vitro evaluation, confocal laser scanning microscopy, and in vivo pharmacokinetic studies. Pharm Dev Technol. 2024;29(1):40-51. doi:10.1080/10837450.20 23.2294278
- 72. Albash R, Abdelbary AA, Refai H, El-Nabarawi MA. Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: In vitro, ex vivo, and in vivo evaluation. Int J Nanomedicine. 2019;14:1953-68. doi:10.2147/ijn.S196771
- 73. Makhlouf A, Elnawawy T. Hair regrowth boosting via minoxidil cubosomes: Formulation development, in vivo hair regrowth evaluation, histopathological examination and confocal laser microscopy imaging. Int J Pharm. 2023;634:122665. doi:10.1016/j. ijpharm.2023.122665
- 74. Jha S, Sharma PK, Malviya R. Liposomal drug delivery system for cancer therapy: Advancement and patents. Recent Pat Drug Deliv Formul. 2016;10(3):177-83. do i:10.2174/1872211310666161004155757
- 75. Miere F, Fritea L, Cavalu S, Vicaș SI. Formulation, characterization, and advantages of using liposomes in multiple therapies. Pharmacophore. 2020;11(3- 2020 :1-12.
- 76. Karn PR, Cho W, Park H-J, Park J-S, Hwang S-J. Characterization and stability studies of a novel liposomal cyclosporin a prepared using the supercritical fluid method: Comparison with the modified conventional bangham method. Int J Nanomedicine. 2013;8:365-77. doi:10.2147/IJN. S39025
- 77. El Maghraby GM, Barry BW, Williams AC. Liposomes and skin: From drug delivery to model membranes. Eur J Pharm Sci. 2008;34(4-5):203-22. doi:10.1016/j. ejps.2008.05.002
- 78. Riccardi D, Baldino L, Reverchon E. Liposomes, transfersomes and niosomes: Production methods and their applications in the vaccinal field. J Transl Med. 2024;22(1):339. doi:10.1186/s12967-024-05160- 4
- 79. Piskin S, Uzunali E. A review of the use of adapalene for the treatment of acne vulgaris. Ther Clin Risk Manag. 2007;3(4):621-4.
- 80. Kajimoto K, Yamamoto M, Watanabe M, Kigasawa K, Kanamura K, Harashima H, et al. Noninvasive and persistent transfollicular drug delivery system

using a combination of liposomes and iontophoresis. Int J Pharm. 2011;403(1-2):57-65. doi:10.1016/j. ijpharm.2010.10.021

- 81. Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: A comprehensive review. J Dermatolog Treat. 2022;33(4):1896-906. doi:10.1080/09546634.20 21.1945527
- 82. Sharma A, Goren A, Dhurat R, Agrawal S, Sinclair R, Trüeb RM, et al. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatol Ther. 2019;32(3):e12915. doi:10.1111/dth.12915
- 83. Hachem R, Assaf A, Numan Y, Shah P, Jiang Y, Chaftari AM, et al. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in highrisk patients with hematological malignancies. Int J Antimicrob Agents. 2017;50(3):384-8. doi:10.1016/j. ijantimicag.2017.03.021
- 84. Muangsanguan A, Linsaenkart P, Chaitep T, Sangta J, Sommano SR, Sringarm K, et al. Hair growth promotion and anti-hair loss effects of by-products arabica coffee pulp extracts using supercritical fluid extraction. Foods. 2023;12(22):4116. doi:10.3390/ foods12224116
- 85. Ingebrigtsen SG, Didriksen A, Johannessen M, Škalko-Basnet N, Holsæter AM. Old drug, new wrapping - a possible comeback for chloramphenicol? Int J Pharm. 2017;526(1-2):538-46. doi:10.1016/j. ijpharm.2017.05.025
- 86. Hanif R, Khan MI, Madni A, Akhtar MF, Sohail MF, Saleem A, et al. Polyoxyethylene lauryl ether (brij-35) and poloxamer 407–based non-ionic surfactant vesicles for dissolution enhancement of tacrolimus. J Pharm Innov. 2023;18(3):1487-99. doi:10.1007/ s12247-023-09737-2
- 87. Roque L, Fernández M, Benito JM, Escudero I. Stability and characterization studies of span 80 niosomes modified with ctab in the presence of nacl. Colloid Surface A 2020;601:124999. doi:10.1016/j. colsurfa.2020.124999
- 88. Teaima MH, El Mohamady AM, El-Nabarawi MA, Mohamed AI. Formulation and evaluation of niosomal vesicles containing ondansetron hcl for trans-mucosal nasal drug delivery. Drug Dev Ind Pharm. 2020;46(5):751-61. doi:10.1080/03639045.20 20.1753061
- 89. Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes--non-ionic surfactant vesicles. J Pharm Pharmacol. 1985;37(12):863-8. doi:10.1111/j.2042-7158.1985.tb04990.x
- 90. Marianecci C, Di Marzio L, Rinaldi F, Celia C, Paolino D, Alhaique F, et al. Niosomes from 80s to present: The state of the art. Adv Colloid Interface Sci. 2014;205:187-206. doi:10.1016/j.cis.2013.11.018
- 91. Rogerson A, Cummings J, Willmott N, Florence AT.

The distribution of doxorubicin in mice following administration in niosomes. J Pharm Pharmacol. 1988;40(5):337-42. doi:10.1111/j.2042-7158.1988. tb05263.x

- 92. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172(1):33-70. doi:10.1016/S0378- 5173(98)00169-0
- 93. Azeem A, Anwer MK, Talegaonkar S. Niosomes in sustained and targeted drug delivery: Some recent advances. J Drug Target. 2009;17(9):671-89. doi:10.3109/10611860903079454
- 94. Khan R, Irchhaiya R. Niosomes: A potential tool for novel drug delivery. J Pharm Investig. 2016;46(3):195- 204. doi:10.1007/s40005-016-0249-9
- 95. Salomon G, Giordano-Labadie F. Surfactant irritations and allergies. Eur J Dermatol. 2022;32(6):677-81. doi:10.1684/ejd.2022.4290
- 96. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride male pattern hair loss study group. J Am Acad Dermatol. 1998;39(4 Pt 1):578-89. doi:10.1016/s0190-9622(98)70007-6
- 97. Baldwin H, Webster G, Stein Gold L, Callender V, Cook-Bolden FE, Guenin E. 50 years of topical retinoids for acne: Evolution of treatment. Am J Clin Dermatol. 2021;22(3):315-27. doi:10.1007/s40257- 021-00594-8
- 98. Gu W, Han W, Luo H, Zhou F, He D, Ma L, et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (chart): A randomised, open-label, phase 3 trial. Lancet Oncol. 2022;23(10):1249-60. doi:10.1016/ S1470-2045(22)00507-1
- 99. Thitipramote N, Imsonpang S, Sukphopetch P, Pradmeeteekul P, Nimkamnerd J, Nantitanon W, et al. Health benefits and safety of red pigmented rice (Oryza sativa L.): In vitro, cellular, and in vivo activities for hair growth promoting treatment. Cosmetics. 2022;9(6):111. doi:10.3390/cosmetics9060111
- 100.Acharya P, Mathur MC. Oxidative stress in alopecia areata: A systematic review and meta-analysis. Int J Dermatol. 2020;59(4):434-40. doi:10.1111/ijd.14753
- 101.Nangare S, Dugam S. Smart invasome synthesis, characterizations, pharmaceutical applications, and pharmacokinetic perspective: A review. Futur J Pharm Sci. 2020;6(1):123. doi:10.1186/s43094-020-00145-8
- 102.Bommannan D, Potts RO, Guy RH. Examination of the effect of ethanol on human stratum corneum in vivo using infrared spectroscopy. J Control Release. 1991;16(3):299-304. doi:10.1016/0168- 3659(91)90006-Y
- 103.Ota Y, Hamada A, Nakano M, Saito H. Evaluation of percutaneous absorption of midazolam by terpenes. Drug Metab Pharmacokinet. 2003;18(4):261-6. doi:10.2133/dmpk.18.261
- 104.Babaie S, Bakhshayesh ARD, Ha JW, Hamishehkar H, Kim KH. Invasome: A novel nanocarrier for transdermal drug delivery. Nanomaterials (Basel). 2020;10(2):341. doi:10.3390/nano10020341
- 105.Yi Q-F, Yan J, Tang S-Y, Huang H, Kang L-Y. Effect of borneol on the transdermal permeation of drugs with differing lipophilicity and molecular organization of stratum corneum lipids. Drug Dev Ind Pharm. 2016;42(7):1086-93. doi:10.3109/03639045.2015.1107 095
- 106.Bagatin E, Costa CS. The use of isotretinoin for acne an update on optimal dosing, surveillance, and adverse effects. Expert Rev Clin Pharmacol. 2020;13(8):885- 97. doi:10.1080/17512433.2020.1796637
- 107.Fernández-García R, Lalatsa A, Statts L, Bolás-Fernández F, Ballesteros MP, Serrano DR. Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale. Int J Pharm. 2020;573:118817. doi:10.1016/j. ijpharm.2019.118817
- 108.Opatha SAT, Titapiwatanakun V, Chutoprapat R. Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery. Pharmaceutics. 2020;12(9):855. doi:10.3390/ pharmaceutics12090855
- 109.Rajan R, Jose S, Mukund VPB, Vasudevan DT. Transferosomes - a vesicular transdermal delivery system for enhanced drug permeation. J Adv Pharm Technol Res. 2011;2(3):138-43. doi:10.4103/2231- 4040.85524
- 110.Matharoo N, Mohd H, Michniak-Kohn B. Transferosomes as a transdermal drug delivery system: Dermal kinetics and recent developments. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024;16(1):e1918. doi:10.1002/wnan.1918
- 111.Fresta M, Mancuso A, Cristiano MC, Urbanek K, Cilurzo F, Cosco D, et al. Targeting of the pilosebaceous follicle by liquid crystal nanocarriers: In vitro and in vivo effects of the entrapped minoxidil. Pharmaceutics. 2020;12(11):1127. doi:10.3390/ pharmaceutics12111127
- 112.Mir-Palomo S, Nácher A, Ofelia Vila-Busó MA, Caddeo C, Manca ML, Saurí AR, et al. Co-loading of finasteride and baicalin in phospholipid vesicles tailored for the treatment of hair disorders. Nanoscale. 2020;12(30):16143-52. doi:10.1039/d0nr03357j
- 113.Oku N, Macdonald RC. Formation of giant liposomes from lipids in chaotropic ion solutions. Biochimica et Biophysica Acta. 1983;734(1):54-61. doi:10.1016/0005-2736(83)90074-3
- 114.Gupta P, Mazumder R, Padhi S. Glycerosomes: Advanced liposomal drug delivery system. Indian J Pharm Sci 2020;82(3):385-97. doi:10.36468/ pharmaceutical-sciences.661
- 115.Vitonyte J, Manca ML, Caddeo C, Valenti D, Peris JE, Usach I, et al. Bifunctional viscous nanovesicles co-loaded with resveratrol and gallic acid for skin

protection against microbial and oxidative injuries. Eur J Pharm Biopharm. 2017;114:278-87. doi:10.1016/j. ejpb.2017.02.004

- 116.Barichello JM, Yamakawa N, Kisyuku M, Handa H, Shibata T, Ishida T, et al. Combined effect of liposomalization and addition of glycerol on the transdermal delivery of isosorbide 5-nitrate in rat skin. Int J Pharm. 2008;357(1):199-205. doi:10.1016/j. ijpharm.2008.01.052
- 117.Manca ML, Zaru M, Manconi M, Lai F, Valenti D, Sinico C, et al. Glycerosomes: A new tool for effective dermal and transdermal drug delivery. Int J Pharm. 2013;455(1):66-74. doi:10.1016/j.ijpharm.2013.07.060
- 118.Karami Z, Hamidi M. Cubosomes: Remarkable drug delivery potential. Drug Discov Today. 2016;21(5):789- 801. doi:10.1016/j.drudis.2016.01.004
- 119.How KN, Yap WH, Lim CLH, Goh BH, Lai ZW. Hyaluronic acid-mediated drug delivery system targeting for inflammatory skin diseases: A mini review. Front pharmacol 2020;11:1105. doi:10.3389/ fphar.2020.01105
- 120.Asrorov AM. Chapter 16 hyalurosomes: A newer approach for drug delivery. In: Nayak AK, Hasnain MS, Aminabhavi TM, Torchilin VP, editors. Systems of nanovesicular drug delivery. NewYork: Academic Press; 2022.
- 121. Jain H, Patel J, Joshi K, Patel P, Upadhyay U. Ethosomes: A novel drug carrier. Int J Clin Pract. 2011;7(1):1-4.
- 122.Koushlesh Kumar M, Chanchal Deep K, Shekhar V, Anil Kumar S, Deepak Kumar D, Pankaj K, et al. Transethosomes and nanoethosomes: Recent approach on transdermal drug delivery system. In: Muhammad Akhyar F, editor. Nanomedicines. Rijeka: IntechOpen; 2019.
- 123.Fongemie J, Felix-Getzik E. A review of nebivolol pharmacology and clinical evidence. Drugs. 2015;75(12):1349-71. doi:10.1007/s40265-015-0435-5
- 124.Ciotti SN, Weiner N. Follicular liposomal delivery systems. J Liposome Res. 2002;12(1-2):143-8. doi:10.1081/lpr-120004787
- 125.Han I, Kim M, Kim J. Enhanced transfollicular delivery of adriamycin with a liposome and iontophoresis. Exp Dermatol 2004;13(2):86-92. doi:10.1111/j.0906- 6705.2004.00123.x.
- 126.Bath BD, Scott ER, Phipps JB, White HS. Scanning electrochemical microscopy of iontophoretic transport in hairless mouse skin. Analysis of the relative contributions of diffusion, migration, and electroosmosis to transport in hair follicles. J Pharm Sci. 2000;89(12):1537-49. doi:10.1002/1520- 6017(200012)89:12<1537::AID-JPS4>3.0.CO;2-J
- 127.Chen T, Langer R, Weaver JC, editors. Skin electroporation causes molecular transport across the stratum corneum through localized transport regions. J Investig Dermatol Symp Proc. 1998;3(2):159-65. doi:10.1038/jidsymp.1998.32
- 128.Grewal BS, Naik A, Irwin WJ, Gooris G, de Grauw CJ, Gerritsen HG, et al. Transdermal macromolecular delivery: Real-time visualisation of iontophoretic and chemically enhanced transport using two-photon excitation microscopy. Pharm Res. 2000;17:788-95. doi:10.1023/A:1007595822786
- 129.Mitragotri S. Synergistic effect of enhancers for transdermal drug delivery. Pharm Res. 2000;17:1354- 9. doi:10.1023/A:1007522114438
- 130.Bakshi P, Vora D, Hemmady K, Banga AK. Iontophoretic skin delivery systems: Success and failures. Int J Pharm. 2020;586:119584. doi:10.1016/j. ijpharm.2020.119584
- 131.Warden GD. Electrical safety in iontophoresis. Rehab Manag. 2007;20(2):22-3.
- 132.Curdy C, Kalia YN, Guy RH. Non-invasive assessment of the effects of iontophoresis on human skin invivo. J Pharm Pharmacol. 2001;53(6):769-77. doi:10.1211/0022357011776117
- 133.Alvi SB, Rajalakshmi P, Jogdand A, Sanjay AY, Veeresh B, John R, et al. Iontophoresis mediated localized delivery of liposomal gold nanoparticles for photothermal and photodynamic therapy of acne. Biomater Sci. 2021;9(4):1421-30. doi:10.1039/ d0bm01712d
- 134. Sarheed O, Frum Y. Use of the skin sandwich technique to probe the role of the hair follicles in sonophoresis. Int J Pharm. 2012;423(2):179-83. doi:10.1016/j. ijpharm.2011.12.023
- 135.Busch L, Keziban Y, Dähne L, Keck CM, Meinke MC, Lademann J, et al. The impact of skin massage frequency on the intrafollicular transport of silica nanoparticles: Validation of the ratchet effect on an ex vivo porcine skin model. Eur J Pharm Biopharm. 2021;158:266-72. doi:10.1016/j.ejpb.2020.11.018
- 136.Lademann J, Richter H, Teichmann A, Otberg N, Blume-Peytavi U, Luengo J, et al. Nanoparticles– an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm. 2007;66(2):159-64. doi:10.1016/j.ejpb.2006.10.019
- 137.Radtke M, Patzelt A, Knorr F, Lademann J, Netz RR. Ratchet effect for nanoparticle transport in hair follicles. Eur J Pharm Biopharm. 2017;116:125-30. doi:10.1016/j.ejpb.2016.10.005